reviewed april 2026|next review october 2026|88 physicians psi has verified|778 published studies
Setmelanotide
Setmelanotide (Imcivree) is a melanocortin-4 receptor (MC4R) agonist FDA-approved for chronic weight management in patients with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing. It is the first precision medicine approved for obesity.
Evidence landscape: 778 published studies
187 published items indexed. 23 human studies and 41 animal studies. A targeted evidence base reflecting the rare-disease precision medicine approach.
- 2 Human
- 195 Animal
- 3 Reviews
- 578 Other research
FDA-approved (2020) as Imcivree for three rare genetic obesity disorders: POMC deficiency, PCSK1 deficiency, and LEPR deficiency. Requires genetic testing confirmation before prescription.
The first obesity medication that targets a specific molecular defect. It works only when the genetic defect is in the melanocortin pathway upstream of MC4R. It is not indicated for common obesity.
Selectively activates MC4R, the receptor that signals satiety in the brain. In patients with upstream genetic defects, MC4R never receives the normal satiety signal. Setmelanotide restores that signal directly.
PSI Assessment
For three rare genetic obesity disorders, the hunger signal is broken at a specific molecular step. Setmelanotide, sold as Imcivree, is the first precision medicine approved for obesity: it bypasses the broken step by directly activating the melanocortin-4 (MC4) receptor that tells the brain satiety has been reached. Approved in 2020 for POMC deficiency, PCSK1 deficiency, and LEPR deficiency obesity, it is not a general weight loss medication. It works only when the genetic defect is in the melanocortin pathway upstream of MC4R.
The first precision medicine for obesity. Works by restoring the satiety signal that three rare genetic conditions break.
The mechanism is selective MC4R agonism. In the normal melanocortin pathway, leptin activates LEPR, which signals through POMC and PCSK1 to produce alpha-melanocyte-stimulating hormone (alpha-MSH), which activates MC4R to suppress appetite. When any upstream gene (POMC, PCSK1, or LEPR) is deficient, MC4R never receives the satiety signal. Setmelanotide restores that signal directly at MC4R, bypassing the deficiency. This is why it works for these three specific conditions and not for common obesity where MC4R signaling is intact.
What the evidence supports
FDA-approved for three rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency). The first precision medicine approved for obesity. MC4R agonism is mechanistically validated.
What is not yet established
Efficacy in common (non-genetic) obesity. Whether expanded genetic testing will identify additional responder populations. Long-term safety in pediatric patients.
Research Evidence
The findings below cover what the pivotal trials established for each approved genetic condition.
Evidence by condition
Evidence dimensions across setmelanotide's approved indications. All three approved conditions share the same mechanism: MC4R activation bypassing upstream genetic deficiency.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| POMC Deficiency Obesity | ||||
| PCSK1 Deficiency Obesity | ||||
| LEPR Deficiency Obesity |
The pivotal Phase III trial demonstrated substantial body weight reduction in patients with POMC and LEPR deficiency obesity. Mean weight loss was approximately 25% in POMC-deficient patients and approximately 10% in LEPR-deficient patients over 52 weeks, with substantial reduction in hunger scores.
These are patients with lifelong, previously untreatable severe obesity caused by a single gene defect. The magnitude of weight loss in this population is unprecedented.
The first clinical proof of concept demonstrated dramatic weight loss in two POMC-deficient patients treated with setmelanotide. This case series established that MC4R agonism could bypass the upstream genetic defect.
A proof-of-concept study in two patients led to the full clinical program. The precision medicine rationale was validated at the molecular level.
Extension trials explored setmelanotide in additional rare genetic obesity conditions including Bardet-Biedl syndrome and Alstrom syndrome, expanding the population of patients who may benefit from MC4R restoration.
Whether expanded genetic testing identifies additional responder populations beyond the three originally approved conditions is an active research question.
2 Human|195 Animal|3 Reviews
View all 778 indexed studiesHow Setmelanotide Works
Setmelanotide is a cyclic peptide MC4R agonist that selectively activates melanocortin-4 receptors in the hypothalamus, restoring satiety signaling in patients with genetic defects upstream of MC4R.
Directly activates the MC4 receptor that tells your brain you are full, bypassing the broken genetic step.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
In the normal melanocortin pathway, leptin binds LEPR on hypothalamic neurons, activating a signaling cascade through POMC and PCSK1 to produce alpha-MSH, the body's native MC4R agonist. Alpha-MSH activates MC4R, a Gs-coupled G-protein-coupled receptor (GPCR) on paraventricular nucleus neurons, triggering cAMP signaling that suppresses appetite and increases energy expenditure via sympathetic outflow. When POMC, PCSK1, or LEPR is genetically deficient, alpha-MSH is not produced (or LEPR cannot initiate the cascade), and MC4R receives no satiety signal. Setmelanotide bypasses the entire upstream pathway by directly activating MC4R. This is why it works only in patients with upstream pathway defects and not in common obesity, where MC4R signaling is intact but overridden by other factors.
What is Setmelanotide being studied for?
Researchers are studying Setmelanotide across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Setmelanotide overall. This means a compound can have human studies for one condition but only animal data for another.
POMC Deficiency Obesity
·FDA ApprovedFDA-approved. POMC deficiency prevents production of alpha-MSH, the natural MC4R activator. Setmelanotide restores the signal directly at MC4R.
Limitations: Extremely rare condition. Small trial populations due to disease rarity. Open-label trial design.
PCSK1 Deficiency Obesity
·FDA ApprovedFDA-approved. PCSK1 deficiency prevents processing of POMC into active alpha-MSH. Same downstream MC4R restoration mechanism.
Limitations: Extremely rare. Limited number of identified patients worldwide.
LEPR Deficiency Obesity
·FDA ApprovedFDA-approved. LEPR deficiency prevents leptin from initiating the melanocortin cascade. Setmelanotide bypasses the leptin receptor entirely.
Limitations: Rare condition. Hunger score improvement was demonstrated but long-term weight maintenance data is limited.
Safety and Regulatory Status
FDA Status: FDA-approved (2020) as Imcivree. REMS (Risk Evaluation and Mitigation Strategy) program required.
Administration: Daily subcutaneous injection. Requires genetic testing confirmation of POMC, PCSK1, or LEPR deficiency before prescription.
The most common side effects are skin hyperpigmentation (related to melanocortin receptor activation on melanocytes), injection site reactions, and spontaneous penile erections. The REMS program ensures appropriate patient selection through mandatory genetic testing.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Setmelanotide discussion.
Comparison and Related Research
Setmelanotide occupies a unique position as a precision medicine for genetic obesity, distinct from general weight loss medications.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Phase III pivotal trial in patients with LEPR or POMC deficiency obesity. Substantial body weight reduction in patients with lifelong untreatable severe obesity. Basis for the 2020 FDA approval.Clement K et al., 2020 in Nat Med. View on PubMed
- 2.First clinical demonstration of MC4R agonist therapy in POMC-deficient patients. Dramatic reduction in hyperphagia and body weight. Proof of concept for the precision medicine approach.Kuhnen P et al., 2016 in Nat Med. View on PubMed
- 3.Extension trials in additional rare genetic obesity conditions. Expanded the population of patients who may benefit from MC4R restoration therapy.Haqq AM et al., 2022 in Lancet Diabetes Endocrinol. View on PubMed
- 4.Study in patients with heterozygous MC4R mutations. Limited efficacy because the drug target itself is deficient. Confirmed the precision requirement: setmelanotide works upstream of MC4R deficiency, not at it.Collet TH et al., 2017 in Nat Med. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.